‘Absolutely Important’ to Develop Better Ways to Predict Kidney Cancer Recurrence, Says Expert
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Why European Experts Cautiously Recommend Pembrolizumab to Treat High-Risk Kidney Cancer Following Surgery
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Urologists Should Make Patients With Metastatic Kidney Cancer Aware that not All Trials Have Positive Results, Says Expert
Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.
Adjuvant Treatment of Kidney Cancer Remains an Uncertainty, Says Expert
“Much more research” is needed to advance the adjuvant treatment of patients with kidney cancer, according to an expert from the Royal Free London NHS Foundation Trust.